# How Biotech Teams Map a Competitive Target Landscape

Canonical URL: https://biopharmsignal.com/use-cases/biotech-competitive-intelligence/map-biotech-target-landscape
Role: [Biotech Competitive Intelligence Teams](https://biopharmsignal.com/use-cases/biotech-competitive-intelligence.md)
Category: Landscape monitoring
Last updated: 2026-07-26

Build a living market map that changes as programs enter, advance, fail, partner, or disappear.

## The Situation

A biotech strategy, business development, or competitive intelligence team needs a current view of every relevant program around a target or mechanism.

### Best Fit

Competitive intelligence, business development, corporate strategy, clinical, regulatory, and commercial teams inside biotech and pharmaceutical companies.

## The Challenge

Static landscape slides become outdated quickly. Program names, company ownership, development stages, and strategic priorities change throughout the year.

## How To Think About The Task

A target landscape should function as a living record of competitive change. Static slides become stale when programs enter trials, change owners, report data, pause, or disappear.

The landscape needs clear inclusion rules and a change log so users can distinguish a current market map from a collection of historical company claims.

### Define the scientific boundary

Specify target, mechanism, modality, indication, geography, and stage criteria. Adjacent programs can be included, but their relationship should be labeled rather than implied.

### Normalize identity and ownership

Track program-code changes, company renaming, licensing, options, and acquisitions. Without ownership history, the same asset may appear twice or disappear after a transaction.

### Make change the main output

Record new entry, advancement, delay, evidence, discontinuation, and transaction events. Stakeholders usually need to know what changed since the previous review, not reread the entire landscape.

## Illustrative Example

### Illustrative quarterly landscape update

A target map contains thirty programs. During the quarter, two enter the clinic, one changes owner, three report data, and two are discontinued. The update highlights these eight changes and their implications while preserving the full source-linked table.

The strategy discussion can then focus on crowding, validation, class risk, and whitespace rather than data cleanup.

### Questions To Answer Before Making A Decision

- What qualifies a program for inclusion?
- Are program identity and ownership current?
- What changed since the last review?
- Which change affects internal strategy?

## A Repeatable Workflow

1. Define inclusion criteria by target, modality, indication, geography, and development stage.
2. Normalize company names, program codes, ownership, and synonyms.
3. Track stage, trial design, latest evidence, next event, and source for every program.
4. Classify changes such as new entry, progression, delay, discontinuation, or transaction.
5. Review the map on a fixed cadence and after major conferences or readouts.

## Signals To Keep Visible

- New programs and trial starts
- Stage and timing changes
- Clinical evidence and safety
- Licensing and ownership changes
- Program discontinuations

## Common Mistakes

- Building the landscape once for a presentation
- Ignoring synonyms and program-code changes
- Tracking stage without the evidence behind it

## Deliverable

A source-linked landscape table and change log showing who is active, what has changed, and which events are next.

## Practical Outcome

The team maintains a shared market view and can identify whitespace, crowding, and meaningful competitive changes earlier.

## Where BioPharmSignal Fits

Use LiveFeed and company pages for source-linked monitoring, the PDUFA Calendar for upcoming FDA milestones, and watchlists or alerts to keep relevant tickers and keywords visible. The workflow still requires independent research and judgment.

## Frequently Asked Questions

### Who is this workflow for?

It is designed for biotech competitive intelligence teams and adjacent biotech research users who need a repeatable, source-linked way to complete this task.

### What should this workflow produce?

A source-linked landscape table and change log showing who is active, what has changed, and which events are next.

### What is the practical benefit?

The team maintains a shared market view and can identify whitespace, crowding, and meaningful competitive changes earlier.

## Related Workflows

- [How Biotech Teams Monitor Competitor Clinical Progress](https://biopharmsignal.com/use-cases/biotech-competitive-intelligence/monitor-competitor-clinical-progress.md)
- [How Biotech BD Teams Identify Partnership Signals](https://biopharmsignal.com/use-cases/biotech-competitive-intelligence/identify-biotech-partnership-signals.md)
- [Track same-indication development programs](https://biopharmsignal.com/use-cases/biotech-competitive-intelligence/track-same-indication-development-programs.md)

Format note: This is an illustrative workflow guide, not a named customer testimonial or a claim of investment performance.